Search Results

You are looking at 101 - 110 of 886 items for :

  • "risk factor" x
  • Refine by Access: All x
Clear All
Full access

A Survey of the National Comprehensive Cancer Network on Approaches Toward Addressing Patients’ Transportation Insecurity

Krisda H. Chaiyachati, Diana Krause, Jessica Sugalski, Evan M. Graboyes, and Lawrence N. Shulman

infrastructure that is not suitable for patients with cancer; and inability to access ride services. 1 , 2 Transportation insecurity is a social risk factor 3 —adverse social conditions associated with poor health—that frequently co-occurs with other social risk

Full access

Risk and Timing of Neutropenic Events in Adult Cancer Patients Receiving Chemotherapy: The Results of a Prospective Nationwide Study of Oncology Practice

Jeffrey Crawford, David C. Dale, Nicole M. Kuderer, Eva Culakova, Marek S. Poniewierski, Debra Wolff, and Gary H. Lyman

2005 ; 23 : 569 – 575 . 16. Lyman GH Lyman CH Agboola O . Risk models for predicting chemotherapy-induced neutropenia . Oncologist 2005 ; 10 : 427 – 437 . 17. Gomez H Hidalgo M Casanova L . Risk factors for treatment

Full access

Bone Mineral Density Testing Disparities Among Patients With Breast Cancer Prescribed Aromatase Inhibitors

John Charlson, Elizabeth C. Smith, Alicia J. Smallwood, Purushottam W. Laud, and Joan M. Neuner

along with other risk factors for fracture. 3 , 5 – 8 Although a few studies early in the use of AIs suggested that adherence to these guidelines was suboptimal, 9 – 13 there are few recent data. As consensus about the importance of AIs in HT regimens

Full access

Delayed Recovery and Increased Severity of Paclitaxel-Induced Peripheral Neuropathy in Patients With Diabetes

Pilar de la Morena Barrio, María Ángeles Vicente Conesa, Enrique González-Billalabeitia, Edgar Urrego, Elisa García-Garre, Elena García-Martínez, Marta Zafra Poves, Vicente Vicente, and Francisco Ayala de la Peña

have DM. 14 , 15 Because DM is itself a cause of peripheral neuropathy, PIPN might be more prevalent and severe in patients with breast cancer and DM. However, the available evidence is limited for considering DM a risk factor for PIPN. Several case

Full access

NCCN Task Force Report: Bone Health in Cancer Care

Julie R. Gralow, J. Sybil Biermann, Azeez Farooki, Monica N. Fornier, Robert F. Gagel, Rashmi Kumar, Georgia Litsas, Rana McKay, Donald A. Podoloff, Sandy Srinivas, and Catherine H. Van Poznak

effects on bone metabolism. The hormone deprivation state resulting from certain cancer therapies enhances osteoclastic bone resorption, promoting bone loss. Osteoporosis risk factors unique to patients with cancer include chemotherapy-induced menopause

Full access

Preoperative Distress Predicts Persistent Pain After Breast Cancer Treatment: A Prospective Cohort Study

Mathias Kvist Mejdahl, Birgitte Goldschmidt Mertz, Pernille Envold Bidstrup, and Kenneth Geving Andersen

Identify psychological risk factors for PPBCT that may be targeted in preventive interventions Background Persistent pain after breast cancer treatment (PPBCT) affects 25% to 60% of patients treated for breast cancer, 1 may persist for

Full access

Cancer Type and Risk of Newly Diagnosed Depression Among Elderly Medicare Beneficiaries With Incident Breast, Colorectal, and Prostate Cancers

Monira Alwhaibi, Usha Sambamoorthi, Suresh Madhavan, Thomas Bias, Kimberly Kelly, and James Walkup

). These dimensions are an individual's physical make-up, social support, access to care, health behaviors, psychological factors, biological risk factors, treatment factors, community resources, and geographic region. Methods Data Source SEER

Full access

Low Molecular Weight Heparins as Extended Prophylaxis Against Recurrent Thrombosis in Cancer Patients

Cocav A. Engman and Leo R. Zacharski

responsible for the content and editorial decisions regarding this manuscript. References 1. Heit JA Silverstein MD Mohr DN . Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study . Arch Intern

Full access

Optimal Neoadjuvant Strategies for Locally Advanced Rectal Cancer by Risk Assessment and Tumor Location

Anurag Saraf, Hannah J. Roberts, Jennifer Y. Wo, and Aparna R. Parikh

enlarged lateral nodes. Among enrolled patients, more than half had either mesorectal fascia involvement or cN2 disease, with 60% having ≥2 high-risk factors and 30% having ≥3 high-risk factors. The primary endpoint of 3-year disease-related treatment

Full access

Trends in the Incidence and Outcomes of Hospitalized Cancer Patients With Clostridium difficile Infection: A Nationwide Analysis

Arjun Gupta, Raseen Tariq, Ryan D. Frank, Gary W. Jean, Muhammad S. Beg, Darrell S. Pardi, David H. Johnson, and Sahil Khanna

, prevention strategies, and newer treatment modalities for CDI. 4 – 9 Patients with cancer are particularly vulnerable to CDI, which is attributed to traditional risk factors such as age; cancer itself; hospitalization and health care exposure; chemotherapy